Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, and Colleagues Discuss GOZILA Platform for CRC

Commentary
Podcast

Tanios Bekaii-Saab, MD, details the GOZILA platform for colorectal cancer with experts Kristen Ciombor, MD, MSCI, and John Strickler, MD.

This week, CancerNetwork® turns to the second episode in its 3-part series focused on colorectal cancer. Tanios Bekaii-Saab, MD, medical director of the Cancer Clinical Research Office and vice chair and section chief for Medical Oncology at the Mayo Clinic in Phoenix, Arizona, led a discussion with Kristen Ciombor, MD, MSCI, associate professor of medicine at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and John Strickler, MD, associate professor of medicine and co-leader of the Molecular Tumor Board at Duke University School of Medicine in Durham, North Carolina.

This episode’s discussion turns to the GOZILA platform and its international collaborators. The experts expand on this platform and what it means for drug development as well as genetic testing in gastrointestinal malignancies.

Tune in next week for the third and final part of this conversation on colorectal cancer. Take a listen to the first episode of this series:

  • Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, Talks COLOMATE Platform in CRC With Experts

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Recent Videos
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Related Content